 Scholar Rock Holding Corp NASDAQ: SRRK announced new data from the Phase 2 TOPAZ trial extension period evaluating apitegromab in non-ambulatory patients with Types 2 and 3 Spinal Muscular Atrophy SMA receiving an SMN therapy. The trial assessed patient outcomes after 24 months. 